GlassScriptPhysician profile
Pallavi Joshi
NPI 1750765442
$2,005.56
in general payments reported to CMS, 2019-2025
11 companies · $92.66 in 2025
The $92.66 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $688 · 2023: $632 · 2024: $592 · 2025: $92.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $701.48 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $475.47 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $335.13 | 2022 | |
| Roche Diagnostics Corporation | $228.24 | 2023-2024 | |
| Alkermes, INC. | $94.03 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $64.43 | 2023-2024 | |
| Lilly USA, LLC | $59.18 | 2023 | |
| Supernus Pharmaceuticals, INC. | $32.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.40 | 2023 | Rexulti |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pallavi Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.